CURRENT PARTICIPANTS IN THE COMPANION DIAGNOSTICS INDUSTRY In Vitro Diagnostics, Biomarker and Companion Diagnostics Companies...

Transcription

1 CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THIS STUDY... 1 SCOPE OF REPORT... 1 METHODOLOGY AND INFORMATION SOURCES... 2 INTENDED AUDIENCE... 2 ANALYST CREDENTIALS... 2 RELATED REPORTS... 3 BCC ONLINE SERVICES... 3 DISCLAIMER... 3 CHAPTER TWO: SUMMARY... 4 SUMMARY... 4 SUMMARY TABLE U.S. NET SALES OF ONCOTYPE AND TROFILE THROUGH 2015 ($ MILLIONS)... 5 SUMMARY FIGURE U.S. NET SALES OF ONCOTYPE AND TROFILE ($ MILLIONS)... 6 CHAPTER THREE: OVERVIEW, STRUCTURE AND SIGNIFICANCE OF THE COMPANION DIAGNOSTICS INDUSTRY... 7 COMPANION DIAGNOSTICS AS A NEW TREND IN PERSONALIZED MEDICINE... 7 HISTORICAL OVERVIEW... 7 TABLE 1 PERCENTAGE OF PRODUCTS IN EACH SECTOR OF THE COMPANION DIAGNOSTICS INDUSTRY (%)... 8 FIGURE 1 PERCENTAGE OF PRODUCTS IN EACH SECTOR OF THE COMPANION DIAGNOSTICS INDUSTRY... 8 PERSONALIZED MEDICINE TREND OVERVIEW... 8 TABLE 2 OVERVIEW OF PERSONALIZED MEDICINE PRODUCTS... 9 TABLE 3 PERCENTAGE OF EACH PERSONALIZED MEDICINE PRODUCT CATEGORY IN 2008 AND THEIR FORECAST, 2008 AND 2012 (%) FIGURE 2 PERCENTAGE OF EACH PERSONALIZED MEDICINE PRODUCT CATEGORY IN 2008 AND THEIR FORECAST, 2008 AND 2012 (%) FIGURE 2 (CONTINUED) TABLE 4 ESTIMATE FOR COMPANION DIAGNOSTICS TEST MARKET FOR THERAPY SELECTION, THROUGH 2015 ($ MILLIONS)... 12

2 CURRENT PARTICIPANTS IN THE COMPANION DIAGNOSTICS INDUSTRY In Vitro Diagnostics, Biomarker and Companion Diagnostics Companies In Vitro Diagnostics Companies Biomarker Research Companies Companion Diagnostics Companies Laboratory Test Services Companies (CLIA Laboratories) Pharmaceutical Companies Regulatory Entities, Insurance Companies and Healthcare Providers Regulatory Entities Insurance Companies Healthcare Providers Patients, Physicians and Public Opinion as Additional Drivers of the Companion Diagnostic Industry Patients, Physicians and (Continued) Organizations Supporting the Personalized Medicine Approach FIGURE 3 DRIVERS OF COMPANION DIAGNOSTICS INDUSTRY CHALLENGES AND OBSTACLES TO COMPANION DIAGNOSTICS INDUSTRY DEVELOPMENT Challenges and obstacles of (Continued) FIGURE 4 CHALLENGES OF COMPANION DIAGNOSTICS INDUSTRY BIOMARKERS MARKET AS BASIS FOR THE COMPANION DIAGNOSTICS INDUSTRY TABLE 5 GLOBAL BIOMARKER MARKET ($ BILLIONS) TABLE 6 WORLDWIDE MARKET FOR BIOMARKERS ACCORDING TO RESEARCH AREAS IN 2008 ($ BILLIONS) CANCER BIOMARKERS CARDIOVASCULAR DISEASE BIOMARKERS CNS DISORDERS BIOMARKERS IN VITRO DIAGNOSTICS (IVD) INDUSTRY AS A DRIVER FOR THE COMPANION DIAGNOSTICS FIELD TABLE 7 ESTIMATE FOR MAJOR PLAYERS OF IVD COMPANIES IN 2010 (%) EFFECT OF THE REGULATORY ASPECT ON COMPANION DIAGNOSTICS INDUSTRY DEVELOPMENT TABLE 8 COMPANION DIAGNOSTICS, ASSOCIATED DRUGS AND REGULATORY APPROVAL STATE... 26

3 COMPANION DIAGNSOTICS COST AND REIMBURSMENT POLICIES AS DRIVERS FOR INDUSTRY DEVELOPMENT TABLE 9 COMPANION DIAGNOSTICS COST EXAMPLES (DOLLARS) TABLE 10 EXAMPLES OF COMPANION DIAGNOSTICS EFFECT ON HEALTHCARE SAVINGS ($ MILLIONS) GENERAL IMPACT OF PERSONALIZED MEDICINE TREND ON MARKET DEVELOPMENT IN OTHER INDUSTRIES TABLE 11 MARKET SEGMENT ESTIMATES IN PERSONALIZED MEDICINE 2010 AND 2015 ($ BILLIONS) GENERAL IMPACT OF PERSONALIZED (CONTINUED) GENERAL IMPACT OF PERSONALIZED (CONTINUED) ADDITIONAL PERSONOLIZED MEDICINE PRODUCTS ON THE MARKET TABLE 12 ADDITIONAL PERSONALIZED MEDICINE PRODUCTS ON THE MARKET FOR THE GENERAL PUBLIC ($) Direct to Consumer Genetic Tests or At Home Genetic Tests Direct to Consumer (Continued) Personal Genome Sequencing PATENT APPLICATIONS FOR COMPANION DIAGNOSTICS AND BIOMARKERS TABLE 13 PATENT APPLICATIONS WORLDWIDE IN DIFFERENT BIOMARKER RESEARCH FIELDS, FIGURE 5 PATENT APPLICATION WORLDWIDE IN DIFFERENT BIOMARKER RESEARCH FIELDS, EXAMPLES OF RECENT PATENT APPLICATIONS AND GRANTED PATENTS IN THE COMPANION DIAGNOSTICS INDUSTRY Power3/StemTroniX Aveo Pharmaceuticals Clarient Inc Entelos CURRENT TECHNIQUES AND TECHNOLOGIES FOR COMPANION DIAGNOSTICS TABLE 14 ADVANTAGES AND DISADVANTAGES OF MOST COMMON TECHNIQUES FOR COMPANION DIAGNOSTICS DIGITAL PATHOLOGY AND QUANTITATIVE IMMUNOSTAINING AS A NEW TREND IN COMPANION DIAGNOSTIC ASSAY DEVELOPMENT NEW SCIENTIFIC APPROACHES TO COMPANION TEST DEVELOPMENT... 42

4 MicroRNA (mirna) Profiling Imaging as a New Approach to Companion Diagnostics Tests Cognitive Diagnostics as Companion Diagnostics Test GENETIC KNOWLEDGE AND CLINICIAN OPINION AS DRIVERS FOR COMPANION DIAGNOSTICS MARKET TABLE 15 STATISTICS IN THE U.S. FOR PHYSICIAN OPINION REGARDING COMPANION DIAGNOSTIC TESTS AS PART OF DIAGNOSIS AND PATIENT TREATMENT (%) TABLE 16 CURRENT STATISTICS ON PHYSICIAN OPINION IN DIFFERENT ASPECTS OF PERSONALIZED MEDICINE IN THE U.S. (%) TABLE 16 (CONTINUED) LIST OF COMPANION DIAGNOSTICS COMPANIES AND EVALUATION OF MARKET PARTICIPANTS TABLE 17 CURRENT MARKET PARTICIPANTS IN COMPANION DIAGNOSTICS TABLE 17 (CONTINUED) TABLE 17 (CONTINUED) TABLE 17 (CONTINUED) TABLE 17 (CONTINUED) CURRENT MARKET ANALYSIS Roche Diagnostics Qiagen DAKO, Quest Diagnostics and LabCorp Other Competitors in the Market Newcomers to Companion Diagnostics Field Life Technologies GenProbe GE Healthcare Acquisitions and Partnerships Trend Major Pharmaceutical Companies as Partners for Companion Diagnostics Companies TABLE 18 EXAMPLES OF PARTNERSHIPS BETWEEN PHARMA AND DIAGNOSTIC COMPANIES AND TESTS DEVELOPED BETWEEN 2007 AND TABLE 19 NUMBER AND PERCENTAGE OF DEALS IN COMPANION DIAGNOSTICS ACCORDING TO RESEARCH AREAS Failures and Lessons from Companion Diagnostics Development Nanosphere Inc

5 Perlegen Sequenom Companion Tests as a Strategy to Improve Drug Sales Performance Companion Diagnostics as a Strategy for Failing Drugs CHAPTER FOUR: COMPANION DIAGNOSTICS INDUSTRY OVERVIEW IN DIFFERENT RESEARCH AREAS CURRENT PRODUCTS FOR COMPANION DIAGNOSTICS IN CANCER OVERVIEW TABLE 20 COMMON COMPANION DIAGNOSTIC TESTS IN CANCER APPLICATIONS TABLE 20 (CONTINUED) MAIN COMPANION DIAGNOSTICS ASSAY IN ONCOLOGY DRUG MARKET Her2 Test Manufacturers of Her2/neu Assay Manufacturers (Continued) Manufacturers (Continued) Kirsten Ras Sarcoma (KRAS) Test KRAS Test Market Participants TABLE 21 PRICE COMPARISON FOR DIFFERENT KRAS TEST MANUFACTURERS (DOLLARS) EGFR Expression Test Manufacturers of EGFR Kits UGT1A1 test Genetic Assays for Breast Cancer Prognosis BRCA1/ Aviara Breast Cancer Index/Cancer Type ID/ Aviara MGI MammaPrint Oncotype Dx Mammostrat Market Analysis for Cancer Prognosis Testing TABLE 22 SALES OF ONCOTYPE DX WORLDWIDE, THROUGH 2015 ($ MILLIONS) FIGURE 6 SALES OF ONCOTYPE DX WORLDWIDE, THROUGH 2015 ($ MILLIONS) Additional Molecular Markers and Products as Companion Diagnostics for Drug Response... 71

6 Target GI Analysis for Erbitux/Vectibix/Fluorouracil/Camptosar Treatments BCR ABL Analysis for Gleevec Treatment Thiopurine S methyltransferase (TPMT) Activity for Purinethol/Thioguanine/ Azathioprine Treatments Deficiency of Dihydropyrimidine Dehydrogenase (DPD) Activity for 5 Fluorouracil CupPrint for Chemotherapy Treatments G6PD Deficiency for Elitek Treatment PGx Predict for Rituximab Treatment c Kit for Gleevec Treatment in Stomach Cancer CD33 Marker for Mylotarg Treatment CD25 Marker for Ontak Therapy SUMMARY OF COMPANION DIAGNOSTICS ONCOLOGY MARKET TABLE 23 MARKET SHARE FOR COMPANION DIAGNOSTICS KIT DEVELOPERS IN THE ONCOLOGY MARKET, 2010 (%) FIGURE 7 MARKET SHARE FOR COMPANION DIAGNOSTICS KIT DEVELOPERS IN ONCOLOGY MARKET, 2010 (%) INFLUENCE OF CANCER STATISTICS, HEALTHCARE COSTS AND DRUG MARKET ON COMPANION DIAGNOSTICS DEVELOPMENT CANCER STATISTICS OVERVIEW TABLE 24 TOTAL U.S. CANCER STATISTICS AS ESTIMATED BY ACS AND NCI, Breast Cancer Lung Cancer Colorectal Cancer Leukemia HEALTHCARE COSTS AS A FACTOR FOR COMPANION DIAGNOSTICS DEVELOPMENT TABLE 25 AVERAGE ANNUAL HEALTHCARE COST FOR DIFFERENT TYPES OF CANCER IN THE U.S. AND AMOUNT SPENT ON SCIENTIFIC RESEARCH IN KRAS Companion Diagnostics as an Example for New Health Economics Model TABLE 26 ESTIMATE FOR COST SAVINGS USING COMPANION DIAGNOSTIC TEST FOR KRAS IN COLORECTAL CANCER PATIENTS... 78

7 EFFECT OF DRUG MARKET ON COMPANION DIAGNOSTICS PRODUCT DEVELOPMENT TABLE 27 EXAMPLES OF DRUGS SALES WORLDWIDE ASSOCIATED WITH COMPANION DIAGNOSTICS TESTS ON THE MARKET ($ BILLIONS) Herceptin and Her2 Test Vectibix and KRAS test PARTNERSHIPS BETWEEN COMPANION DIAGNOSTICS COMPANIES AND THE PHARMACEUTICAL INDUSTRY IN THE ONCOLOGY SECTOR OVERVIEW TABLE 28 EXAMPLES OF PARTNERSHIPS BETWEEN COMPANION DIAGNOSTICS COMPANIES AND THE PHARMACEUTICAL INDUSTRY IN ONCOLOGY, Qiagen/DxS and Partnerships DxS/ Amgen DxS/ Bristol Myers Squibb/ImClone Systems DxS/ Exosome Diagnostics DxS/ Genzyme Corporation DxS/AstraZeneca DxS/Boehringer Amgen/Lab Almac Diagnostics Partnerships Almac Diagnostics/Eli Lilly Almac Diagnostics/Merck KGaA and U.K. Medical Research Council Abbott Diagnostics/ Pfizer Ipsogen/ ARUP Epigenomics/Bristol Meyer Squibb (BMS) and J&J Celera/Merck and Abbott Laboratories DAKO Partnerships DAKO/Genentech (Roche) DAKO/OSI Pharmaceuticals and BMS DAKO/ Genentech, OSI Pharmaceuticals and Roche Roche/ Plexxikon BioMerieux/Ipsen NEW DEALS AND PARTNERSHIPS BETWEEN PHARMACEUTICAL COMPANIES AND COMPANION DIAGNOSTICS IN ONCOLOGY (DURING 2010) OVERVIEW... 87

8 TABLE 29 RECENT PARTNERSHIPS AND COLLABORATIONS BETWEEN PHARMA, ACADEMICS AND COMPANION DIAGNOSTICS COMPANIES DURING Almac Diagnostics/Aeterna Zentaris Althea DX/The Nicholas Conor Institute for Pediatric Cancer Research BioMerieux/GSK Companion Diagnostics Inc./University of Indianapolis DAKO/AstraZeneca DxS (Qiagen)/Pfizer DxS (Qiagen)/ Johns Hopkins University (JHU) Response Genetics/GSK TCLand Expression/Inserm Ventana Medical Systems/Clavis Pharma ASA ANALYSIS OF PARTNERSHIPS TREND CURRENT COMPANION DIAGNOSTICS TESTS ON THE MARKET FOR METABOLIC DISORDERS OVERVIEW TABLE 30 COMPANION DIAGNOSTICS TESTS ON THE MARKET FOR METABOLIC DISEASES Fibromax Entelos Lipomics Technologies/Tethys Bioscience Biocrates Companion Diagnostics Development Genomas PhyzioType System LDLR/Atorvastatin PARTNERSHIPS BETWEEN COMPANION DIAGNOSTICS COMPANIES AND PHARMACEUTICALS/ACADEMICS IN DEVELOPMENT OF COMPANION ASSAYS FOR METABOLIC DISORDERS OVERVIEW TABLE 31 PARTNERSHIPS AND COLLABORATION BETWEEN COMPANION DIAGNOSTICS COMPANIES AND PHARMACEUTICALS/ACADEMICS, Lipomics Technologies (Tethys Bioscience)/Joslin Diabetes Center (Harvard Medical School) Genomas/ University of Puerto Rico Medical Science Campus decode Genetics/Celera Corp Siemens/LabCorp Celgene Corp./ Agios Pharmaceuticals Inc

9 Biocrates/Pfizer, Altana Pharma MARKET POTENTIAL FOR COMPANION DIAGNOSTICS TESTS IN METABOLIC DISORDERS TABLE 32 STATISTICS AND MARKET SIZE FOR DIABETES, HYPERCHOLESTEROLEMIA AND METABOLIC SYNDROME IN THE U.S., Market Potential for Companion (Continued) CURRENT PRODUCTS FOR COMPANION DIAGNOSTICS IN CARDIOVASCULAR DISEASES OVERVIEW TABLE 33 ANNUAL STATISTICS FOR CARDIOVASCULAR DISEASE IN THE U.S. AND RELATED HEALTHCARE COSTS TABLE 34 CURRENT EXAMPLES OF COMPANION DIAGNOSTICS ON THE MARKET FOR CARDIOVASCULAR DISEASES Companion Diagnostics Test for Coumadin (Warfarin) TABLE 35 ANNUAL STATISTICS FOR COUMADIN TREATMENT IN THE U.S., Manufacturers of Companion Diagnostics Test for Warfarin (Coumadin) Nanosphere Inc AutoGenomics Osmotech/Genmark Diagnostics ParagonDx Entrogen Kimball Genetics Additional Companies Market Analysis for Warfarin Test Competitors Market Analysis for (Continued) TABLE 36 COMPARISON OF FOUR TESTS FOR WARFARIN SENSITIVTY BY FOUR DIFFERENT MANUFACTURERS Companion Diagnostics for Plavix Protein C Deficiency Test for Warfarin Sensitivity Drug Market Associated with Cardiovascular Companion Diagnostics Coumadin Plavix TABLE 37 NET SALES FOR PLAVIX ($ MILLIONS) PARTNERSHIPS BETWEEN COMPANION DIAGNOSTICS COMPANIES AND PHARMACEUTICALS IN CARDIOVASCULAR DISEASES

10 TABLE 38 CURRENT PARTNERSHIPS BETWEEN COMPANION DIAGNOSTICS COMPANIES AND PHARMACEUTICALS OR ACADEMICS IN THE CARDIOVASCULAR DISEASES SECTOR LABCORP/ARCA BIOPHARMA (NUVELO SUBSIDIARY) TABLE 39 U.S. STATISTICS FOR HEART FAILURE AND ANNUAL HEALTHCARE COST AFFOMIX CORP./UNIVERSITY OF MONTREAL PHARMACOGENOMICS CENTRE AND MONTREAL HEART INSTITUTE CELERA CORP./DECODE GENETICS CURRENT PRODUCTS FOR COMPANION DIAGNOSTICS IN CNS DISORDERS TABLE 40 CURRENT COMPANION DIAGNOSTICS TESTS ON THE MARKET FOR CNS DISORDERS DRUG THERAPY HLA B*1502 ALLELE TESTING PHYZIOTYPE PIMS CURRENT COMPANION DIAGNOSTICS COMPANIES DEVELOPING COMPANION ASSAYS IN CNS DISORDERS TABLE 41 CURRENT COMPANION DIAGNOSTICS COMPANIES DEVELOPING COMPANION ASSAYS IN CNS DISORDERS SALADAX BIOMEDICAL CYTOX CURIDIUM MEDICA (AVACTA COMPANY) EXONHIT POPULATION DIAGNOSTICS POWER3 MEDICAL PRODUCTS PROTAGEN CURRENT PARTNERSHIPS BETWEEN DIAGNOSTIC COMPANIES AND THEIR PAHRMACEUTICAL PARTNERS DEVELOPING COMPANION TESTS IN CNS DISORDERS TABLE 42 RECENT PARTNERSHIPS IN THE FIELD OF COMPANION DIAGNOSTICS FOR CNS DISORDERS BETWEEN DIAGNOSTICS AND PHARMACEUTICAL COMPANIES PSYNOVA NEUROTECH (RBM)/ROCHE CURIDIUM MEDICA/TAKEDA SALADAX BIOMEDICAL/BRISTOL MYERS SQUIBB POWER3 MEDICAL PRODUCTS/STEMTRONIX PROTAGEN/ GERMAN FEDERAL MINISTRY OF RESEARCH AND EDUCATION S BIOPHARMA COMPETITION EXONHIT/ALLERGEN

11 STATISTICS, HEALTHCARE COST AND DRUG MARKET FOR CNS DISRODERS AS AN ESTIMATE FOR COMPANION DIAGNOSTICS ASSAY DEVELOPMENT TABLE 43 STATISTICS AND HEALTHCARE COST OF SCHIZOPHRENIA, ALZHEIMER S AND PARKINSON S IN THE U.S ($ BILLIONS) TABLE 44 CURRENT MARKET SIZE FOR NEURODEGENERATION DISORDERS AND SCHIZOPHRENIA IN THE U.S. ($ BILLIONS) SCHIZOPHRENIA AS A MARKET FOR COMPANION DIAGNOSTICS DEVELOPMENT NEURODEGENERATIVE DISORDERS AS A MARKET FOR COMPANION DIAGNOSTICS DEVELOPMENT Parkinson s and Current Drug Treatment TABLE 45 NET SALES OF MIRAPEX AND REQUIP ($ MILLIONS) Alzheimer s and Current Drug Treatment TABLE 46 NET SALES OF NAMENDA AND ARICEPT ($ MILLIONS) BIOMARKER RESEARCH FOR NEURODEGENERATION AS A DRIVER FOR COMPANION DIAGNOSTICS Alzheimer s Biomarker Trend Alzheimer s Biomarker Trend (Continued) Main CSF Biomarkers in Alzheimer s Aβ Total tau protein Hyperphosphorylated tau (P tau) Isoprostanes Cytokines Other Biomarkers Parkinson s Biomarker Trend Future Trends for Development of Companion Diagnostics for CNS Disorders CURRENT PRODUCTS FOR COMPANION DIAGNOSTICS TESTS IN INFECTIOUS DISEASES TABLE 47 CURRENT COMPANION DIAGNOSTICS TESTS ON THE MARKET FOR INFECTIOUS DISEASES GENETIC TEST FOR HLA B TROPISM FOR HIV ASSAY TABLE 48 REVENUES FROM TROFILE SALES BY MONOGRAM/LABCORP ($ MILLIONS) Competitors of Trofile Assay

12 Other New Opportunities for Trofile Use TABLE 49 ENTRY INHIBITORS DRUG DISCOVERY AS NEW OPPORTUNITY FOR TROFILE ASSAY Selzentry as an HIV Trofile Dependent Drug HIV Drug Resistance Tests HIV STATISTICS AND HEALTHCARE COST AS A FACTOR FOR COMPANION DIAGNOSTICS SALES FORECAST TABLE 50 HIV STATISTICS AND HEALTHCARE COST IN THE U.S., HIV DRUG MARKET TABLE 51 MARKET FOR HIV DRUGS WORLDWIDE 2010 AND 2015 ($ BILLIONS) CURRENT PARTNERSHIPS AND COLLABORATIONS FOR COMPANION DIAGNOSTICS FOR INFECTIOUS DISEASES TABLE 52 RECENT PARTNERSHIPS IN THE FIELD OF COMPANION DIAGNOSTICS FOR INFECTIOUS DISEASES BETWEEN DIAGNOSTICS AND PHARMACEUTICAL COMPANIES MitoSciences/University of Oregon LabCorp (Monogram Bioscience)/Pfizer /Shering Plough/Progenics/Gilead Science/Avexa Lab21/Innogenetics CURRENT PRODUCTS FOR COMPANION DIAGNOSTICS IN OTHER DISEASES TABLE 53 CURRENT COMPANION DIAGNOSTICS PRODUCTS IN DIFFERENT CLINICAL APPLICATIONS ALLOMAP GENE PROFILE HLA TESTING COMPANION DIAGNOSTICS TESTS DEVELOPMENT IN DRUG METABOLISM Cytochrome P450 2C9 (CYP2C9) NAT (N acetyltransferase) Amplichip CYP2D6/CYP2C SEROLOGY 7 TEST FOR IBD Serology 7 Test for IBD (Continued) CHAPTER FIVE: MARKET SUMMARY TABLE 54 LIST OF COMPANION DIAGNOSTICS PRODUCTS ON THE MARKET MENTIONED IN THE REPORT TABLE 54 (CONTINUED)

13 TABLE 55 PRODUCTS IN EACH INDUSTRY SECTOR IN THE COMPANION DIAGNOSTICS INDUSTRY (%) FIGURE 8 PRODUCTS IN EACH INDUSTRY SECTOR IN THE COMPANION DIAGNOSTICS INDUSTRY (%) TABLE 56 U.S. NET SALES OF ONCOTYPE AND TROFILE, THROUGH 2015 ($ MILLIONS) FIGURE 9 U.S. NET SALES OF ONCOTYPE AND TROFILE ($ MILLIONS) TABLE 57 ESTIMATE FOR COMPANION DIAGNOSTICS TEST MARKET FOR THERAPY SELECTION, THROUGH 2015 ($ MILLIONS) FIGURE 10 ESTIMATE FOR COMPANION DIAGNOSTICS TEST MARKET FOR THERAPY SELECTION 2010 AND 2015 ($ MILLIONS) CHAPTER SIX SELECTED COMPANIES OVERVIEW ABBOTT LABORATORIES BIOMERIEUX SA CELERA CORP CLINICAL DATA INC DAKO A/S LABCORP QIAGEN MANCHESTER LTD. (FORMER DXS LTD) QUEST DIAGNOSTICS INC ROCHE DIAGNOSTICS (DIVISION OF ROCHE GROUP) CHAPTER SEVEN: DIRECTORY OF COMPANIES DIRECTORY OF COMPANIES DIRECTORY OF COMPANIES (CONTINUED) DIRECTORY OF COMPANIES (CONTINUED) DIRECTORY OF COMPANIES (CONTINUED) DIRECTORY OF COMPANIES (CONTINUED) DIRECTORY OF COMPANIES (CONTINUED) DIRECTORY OF COMPANIES (CONTINUED) DIRECTORY OF COMPANIES (CONTINUED) DIRECTORY OF COMPANIES (CONTINUED) DIRECTORY OF COMPANIES (CONTINUED) DIRECTORY OF COMPANIES (CONTINUED) DIRECTORY OF COMPANIES (CONTINUED) DIRECTORY OF COMPANIES (CONTINUED) DIRECTORY OF COMPANIES (CONTINUED)